{
}
UBS has upgraded its rating for Nordea to "Buy," setting a target price of 143 euros. Analyst Johan Ekblom noted that the bank's third-quarter performance met expectations and highlighted the resumption of its share buyback program.
Sanofi is investing 300 million euros for a 16% stake in a new joint venture with Orano Med to develop radiopharmaceuticals targeting rare cancers, particularly using the radioisotope lead-212. This partnership aims to leverage expertise in biopharma and nuclear technology to advance cancer treatment. The joint venture is valued at 1.9 billion euros, following Sanofi's recent licensing of an experimental drug for neuroendocrine tumors.
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 110 euros ahead of the company's quarterly results due on October 25. Analyst Jo Walton emphasized the importance of assessing the sustainability of Dupixent's success and the market acceptance of Beyfortus.
UBS has maintained a "Buy" rating for Sanofi, setting a target price of 110 euros ahead of the quarterly results due on October 25. Analyst Jo Walton will focus on the sustainability of Dupixent's success and the market acceptance of Beyfortus.
UBS has maintained a 'Buy' rating for Nordea, setting a target price of 143 euros. Analyst Johan Ekblom noted that the bank's third-quarter performance met expectations and highlighted the resumption of its share buyback program. As of October 17, 2024, Nordea's stock was trading at approximately €11.025, reflecting a 5.60% increase.
UBS AG maintains a "Neutral" rating for Sartorius vz shares with a target price of 264 euros, following third-quarter results that showed consolidated sales below expectations but an operating result in line with forecasts. The share price rose 13.9% to EUR 260.30, indicating potential for further growth, despite a 21.7% decline since the start of 2024. Sartorius is set to release its Q3 2024 results on October 17, 2024.
UBS has maintained a "Buy" rating for Merck KGaA, setting a target price of 190 euros following the Group's Capital Markets Day. Analyst Matthew Weston noted that the new targets align with consensus estimates. Merck shares rose 5.7% to EUR 162.95, indicating a potential 16.6% upside. The Q3 2024 financial results are set to be released on November 14, 2024.
UBS AG has maintained a "Buy" rating for Merck KGaA, setting a target price of €190 following the Group's Capital Markets Day. The stock rose by 5.7% to €162.95, indicating a potential upside of 16.6%. Since the start of 2024, Merck's share price has increased by 14.7%, with Q3 2024 results expected on November 14.
UBS AG has maintained a "Neutral" rating on Sartorius vz shares, setting a target price of 264 euros following the third-quarter results. While consolidated sales fell short of expectations, the operating result met forecasts, and a recovery in the BPS division may positively influence the market. Sartorius vz shares rose 13.9% in XETRA trading, though they have declined 21.7% since the start of 2024.
UBS has maintained a 'Neutral' rating for Sartorius with a target price of 264 euros following the third-quarter results. While the laboratory services provider's consolidated sales fell short of consensus estimates, its operating profit met expectations. The recovery in orders within the BPS division may positively influence the market.
Euro
Currency
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs upgrades nordea to buy with target price of 143 euros
13:28 17.10.2024
Sanofi invests 300 million euros in joint venture for radiopharmaceuticals
Euro
Eli Lilly and Company
Orano Group
Bristol-Myers Squibb Company
Novartis AG
AstraZeneca PLC
Bayer AG
Sanofi
FRA
USA
Paul Hudson
Bayer
AstraZeneca
Eli Lilly
Novartis
Show more
13:20 17.10.2024
ubs maintains buy rating for sanofi with target price of 110 euros
12:43 17.10.2024
ubs maintains buy rating for sanofi ahead of quarterly results
12:43 17.10.2024
ubs maintains buy rating for nordea with target price of 143 euros
12:41 17.10.2024
ubs maintains neutral rating for sartorius with target price of 264 euros
12:34 17.10.2024
UBS maintains buy rating for Merck with target price of 190 euros
12:34 17.10.2024
ubs maintains buy rating for merck with target price of 190 euros
12:34 17.10.2024
ubs maintains neutral rating on sartorius vz shares with target price of 264 euros
12:34 17.10.2024
ubs maintains neutral rating for sartorius with target price of 264 euros
12:28 17.10.2024
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Finance Mergers & Acquisitions
Retail and Consumer Goods
Global Financial Events
Market Analysis and Predictions
Banking Regulations
Industry Mergers & Acquisitions
CEO Changes
Global Trade Developments
Supply Chain Management
Workplace Trends
Startups & Entrepreneurship
Hedge Funds & Private Equity
Government Economic Policies
Central Bank Actions
Financial Scams and Security
Government Policies
Banking & Investment Regulations
Countries:
Companies:
Barclays PLC
BNP Paribas SA
Tesla, Inc.
Deutsche Bank RV Global PP
Raiffeisen Bank International AG
JPMorgan Chase & Co.
UniCredit S.p.A.
Apple Inc.
Strabag SE
Citigroup Inc.
Kering S.A. (ADRs)
The Goldman Sachs Group, Inc.
Banco BPM S.p.A.
UBS Group AG
Bank of America Corporation
Morgan Stanley
Berner Kantonalbank AG
Berkshire Hathaway Inc.
Microsoft Corporation
Google Inc.
Currencies:
United States Dollar
Euro
British Pound Sterling
Chinese Yuan
Swiss Franc
Indian Rupee
Japanese Yen
Vietnamese Đồng
Hong Kong Dollar
Australian Dollar
Russian Ruble
Brazilian Real
Filipino Peso
Malaysian Ringgit
United Arab Emirates Dirham
South African Rand
Indonesian Rupiah
South Korean Won
People: